Literature DB >> 16633003

Periampullary and pancreatic incidentaloma: a single institution's experience with an increasingly common diagnosis.

Jordan M Winter1, John L Cameron, Keith D Lillemoe, Kurtis A Campbell, David Chang, Taylor S Riall, Joann Coleman, Patricia K Sauter, Marcia Canto, Ralph H Hruban, Richard D Schulick, Michael A Choti, Charles J Yeo.   

Abstract

BACKGROUND: While incidental masses in certain organs have received particular attention, periampullary and pancreatic incidentalomas (PIs) remain poorly characterized.
METHODS: We reviewed 1944 consecutive pancreaticoduodenectomies (PD) over an 8-year period (April 1997 to October 2005). A total of 118 patients (6% of all PDs) presented with an incidental finding of a periampullary or pancreatic mass. The PI patients were analyzed and compared with the rest of the cohort (NI, nonincidentaloma group, n = 1826).
RESULTS: Thirty-one percent of the PI patients (n = 37) had malignant disease (versus 76% of the NI patients, P < 0.001), 47% (n = 55) had premalignant disease, and the remaining 22% (n = 26) had little or no risk for malignant progression. The 3 most common diagnoses in the PI group were IPMN without invasive cancer (30%), cystadenoma (17%), and pancreatic ductal adenocarcinoma (10%). The PI group had a higher overall complication rate (55% versus 43%, P = 0.02), due in part to a significantly increased rate of pancreatic fistulas (18.4% PI versus 8.5% NI, P < 0.001). Patients in the PI group with malignant disease had a superior long-term survival (median, 30 months, P = 0.01) compared with patients in the NI group with malignant disease (median, 21 months).
CONCLUSIONS: Incidentally discovered periampullary and pancreatic masses comprise a substantial proportion of patients undergoing PD. Roughly three fourths of these lesions are malignant or premalignant, and amenable to curative resection. Resected malignant PIs have favorable pathologic features as compared with resected malignant NIs, and resection of these early lesions in asymptomatic individuals is associated with improved survival, compared with patients with symptomatic disease.

Entities:  

Mesh:

Year:  2006        PMID: 16633003      PMCID: PMC1570557          DOI: 10.1097/01.sla.0000216763.27673.97

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  26 in total

1.  [Observation of pancreatic incidentaloma].

Authors:  T S Kostiuk
Journal:  Klin Khir       Date:  2001-09

2.  Screening CT: rationale.

Authors:  Michael N Brant-Zawadzki
Journal:  Radiographics       Date:  2002 Nov-Dec       Impact factor: 5.333

3.  CT screening: why I do it.

Authors:  Michael Brant-Zawadzki
Journal:  AJR Am J Roentgenol       Date:  2002-08       Impact factor: 3.959

4.  [Cardiac incidentaloma].

Authors:  O Vancollie; E Rombaut; J Donckier
Journal:  Ann Cardiol Angeiol (Paris)       Date:  2001-10

5.  A parathyroid incidentaloma.

Authors:  Erica L Whineray Kelly; Geoff Braatvedt; Richard Harman
Journal:  ANZ J Surg       Date:  2005-05       Impact factor: 1.872

Review 6.  Pituitary incidentalomas.

Authors:  D C Aron; T A Howlett
Journal:  Endocrinol Metab Clin North Am       Date:  2000-03       Impact factor: 4.741

7.  Cystic pancreatic neuroendocrine tumors: is preoperative diagnosis possible?

Authors:  Steven A Ahrendt; Richard A Komorowski; Michael J Demeure; Stuart D Wilson; Henry A Pitt
Journal:  J Gastrointest Surg       Date:  2002 Jan-Feb       Impact factor: 3.452

8.  Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer.

Authors:  A C Tersmette; G M Petersen; G J Offerhaus; F C Falatko; K A Brune; M Goggins; E Rozenblum; R E Wilentz; C J Yeo; J L Cameron; S E Kern; R H Hruban
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

9.  Clinical and pathologic correlation of 84 mucinous cystic neoplasms of the pancreas: can one reliably differentiate benign from malignant (or premalignant) neoplasms?

Authors:  M G Sarr; H A Carpenter; L P Prabhakar; T F Orchard; S Hughes; J A van Heerden; E P DiMagno
Journal:  Ann Surg       Date:  2000-02       Impact factor: 12.969

Review 10.  Adrenal incidentaloma.

Authors:  Geoffrey B Thompson; William F Young
Journal:  Curr Opin Oncol       Date:  2003-01       Impact factor: 3.645

View more
  54 in total

1.  Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Hanno Matthaei; Alexis L Norris; Athanasios C Tsiatis; Kelly Olino; Seung-Mo Hong; Marco dal Molin; Michael G Goggins; Marcia Canto; Karen M Horton; Keith D Jackson; Paola Capelli; Giuseppe Zamboni; Laura Bortesi; Toru Furukawa; Shinichi Egawa; Masaharu Ishida; Shigeru Ottomo; Michiaki Unno; Fuyuhiko Motoi; Christopher L Wolfgang; Barish H Edil; John L Cameron; James R Eshleman; Richard D Schulick; Anirban Maitra; Ralph H Hruban
Journal:  Ann Surg       Date:  2012-02       Impact factor: 12.969

2.  Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms.

Authors:  Brian B Haab; Andrew Porter; Tingting Yue; Lin Li; James Scheiman; Michelle A Anderson; Dawn Barnes; C Max Schmidt; Ziding Feng; Diane M Simeone
Journal:  Ann Surg       Date:  2010-05       Impact factor: 12.969

3.  A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas.

Authors:  Olca Basturk; Seung-Mo Hong; Laura D Wood; N Volkan Adsay; Jorge Albores-Saavedra; Andrew V Biankin; Lodewijk A A Brosens; Noriyoshi Fukushima; Michael Goggins; Ralph H Hruban; Yo Kato; David S Klimstra; Günter Klöppel; Alyssa Krasinskas; Daniel S Longnecker; Hanno Matthaei; G Johan A Offerhaus; Michio Shimizu; Kyoichi Takaori; Benoit Terris; Shinichi Yachida; Irene Esposito; Toru Furukawa
Journal:  Am J Surg Pathol       Date:  2015-12       Impact factor: 6.394

4.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

5.  Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma.

Authors:  Ji Kon Ryu; Hanno Matthaei; Marco Dal Molin; Seung-Mo Hong; Marcia I Canto; Richard D Schulick; Christopher Wolfgang; Michael G Goggins; Ralph H Hruban; Leslie Cope; Anirban Maitra
Journal:  Pancreatology       Date:  2011-07-12       Impact factor: 3.996

6.  A new approach to managing intraductal papillary mucinous pancreatic neoplasms.

Authors:  Paula Ghaneh; John Neoptolemos
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

7.  Solid serous adenoma of the pancreas: a rare form of serous cystadenoma.

Authors:  Madhusudhan R Sanaka; Thomas E Kowalski; Corey Brotz; Charles J Yeo; Peter McCue; Juan Palazzo
Journal:  Dig Dis Sci       Date:  2007-03-28       Impact factor: 3.199

Review 8.  Morphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs).

Authors:  Jan-Bart M Koorstra; Georg Feldmann; Nils Habbe; Anirban Maitra
Journal:  Langenbecks Arch Surg       Date:  2008-02-19       Impact factor: 3.445

9.  Pancreatic cystic neuroendocrine tumors: preoperative diagnosis with endoscopic ultrasound and fine-needle immunocytology.

Authors:  Marshall S Baker; Jamie L Knuth; John DeWitt; Julia LeBlanc; Harvey Cramer; Thomas J Howard; C Maxwell Schmidt; Keith D Lillemoe; Henry A Pitt
Journal:  J Gastrointest Surg       Date:  2007-12-22       Impact factor: 3.452

10.  Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Seung-Mo Hong; David Kelly; Margaret Griffith; Noriyuki Omura; Ang Li; Chung-Pin Li; Ralph H Hruban; Michael Goggins
Journal:  Mod Pathol       Date:  2008-09-26       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.